Sangamo Therapeutics Inc (SGMO) Shares Sold by Sanctuary Wealth Advisors LLC
Sanctuary Wealth Advisors LLC lowered its position in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 268,418 shares of the biopharmaceutical company’s stock after selling 3,458 shares during the quarter. Sangamo Therapeutics comprises about 3.6% of Sanctuary Wealth Advisors LLC’s portfolio, making the stock its 9th largest position. Sanctuary Wealth Advisors LLC’s holdings in Sangamo Therapeutics were worth $4,402,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at $118,000. Amalgamated Bank purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at $158,000. Chicago Equity Partners LLC purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at $192,000. Great West Life Assurance Co. Can raised its stake in shares of Sangamo Therapeutics by 150.3% in the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 7,667 shares during the period. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at $220,000. 66.93% of the stock is currently owned by institutional investors and hedge funds.
Sangamo Therapeutics Inc (NASDAQ SGMO) opened at $24.25 on Monday. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02. Sangamo Therapeutics Inc has a 1-year low of $3.85 and a 1-year high of $27.50.
Several equities research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Wedbush reissued a “neutral” rating and issued a $6.00 target price on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Barclays reissued a “buy” rating and issued a $30.00 target price on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Jefferies Group reissued a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Finally, Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.50.
In other news, Director Saira Ramasastry sold 9,450 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $24.88, for a total value of $235,116.00. Following the transaction, the director now directly owns 9,450 shares in the company, valued at $235,116. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $18.49, for a total transaction of $92,450.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,970 shares of company stock worth $1,299,263. Company insiders own 5.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/03/05/sangamo-therapeutics-inc-sgmo-shares-sold-by-sanctuary-wealth-advisors-llc.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.